

11 March 2025

ASX ANNOUNCEMENT

TRANSITION TO NON-EXECUTIVE DIRECTOR

Paragon Care Limited (ASX: PGC) ("ParagonCare" or the "Company") announces that Mr John Walstab will transition from his executive duties and current role as General Manager Asia/Executive Director to a Non-Executive Director of ParagonCare with effect from 1 April 2025. Mr. Walstab has been a valued member of the Company, as well as being the founder of Quantum Healthcare which also merged with ParagonCare in 2022.

After transitioning from his executive duties, Mr. Walstab will continue to offer his expertise as a valued member of ParagonCare's Board.

The Board is pleased that Mr. Walstab will continue to serve as a Non-Executive Director, which will allow ParagonCare to retain his experience and knowledge of the Company. Mr. Walstab will support ParagonCare as an active member of the Board, while we continue our integration program between CH2 and ParagonCare, as well as supporting our future growth prospects especially in Asia.

David Collins, ParagonCare CEO and Managing Director stated:

"I wish to take this opportunity to thank John for his vision and support in bringing ParagonCare and CH2 together. I believe bringing the two companies together has made us a stronger business and one that now has got a solid platform to grow well into the future throughout the APAC region."

For further information please contact:

David Collins
CEO & Managing Director

david.collins@paragoncare.com.au

This announcement is authorised for release to the market by the Board of Directors of Paragon Care Limited.

About Paragon Care Limited

Paragon Care Limited (ASX:PGC) is an Australian based listed company in the healthcare sector. It is a leading supplier of durable medical equipment, medical devices, consumable medical products and maintenance of technical medical equipment to the health, aged care and veterinary markets throughout Australia, New Zealand and Asia, as well as the distribution of pharmaceuticals, medical consumables, and complementary medicines to the Australian healthcare market.